Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting

ByConnor Hodde

This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting.  To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated…

Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

ByConnor Hodde

WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) — pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored Phase 2 study of pSivida’s Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the two years…

Gene-based agents for the treatment of congenital eye diseases

ByConnor Hodde

Pharmacologists at LMU have developed gene-based agents for the treatment of congenital eye diseases. The first of these is now undergoing a phase-I clinical trial in color-blind patients at the University Medical Center in Tübingen. Is this approach translatable in principle to other visual disorders? Michalakis: About 200 genes have been identified which, when mutated,…

Retinitis Pigmentosa: FDA approves first retinal implant for advanced adult RP

ByConnor Hodde

Retinitis pigmentosa (RP) is a group of inherited disorders characterized by progressive peripheral vision loss and night vision difficulties (nyctalopia) that can lead to central vision loss. The US Food and Drug Administration (FDA) has approved the first retinal implant, the Argus II Retinal Prosthesis System, for adults aged 25 years or older with advanced RP. The…